EBV mRNA vaccine for advanced lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have EBV-positive lymphoma (a type of cancer that has come back or not responded to treatment).
- You have tried at least one or two prior treatments, depending on your lymphoma type.
- You have at least one measurable tumor that can be seen on a scan.
- Your overall health is good (able to care for yourself, expected to live at least 3 more months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This trial tests a new mRNA vaccine designed to help your immune system fight B-cell lymphoma when standard treatments have stopped working or the cancer has returned. The vaccine is given early in testing to see if it is safe and how well it works, while researchers also check how your body responds.
This trial tests a new mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV-related lymphoma. The goal is to see if the vaccine can help the immune system fight the cancer, especially for those whose lymphoma has not fully responded to standard treatments.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This study tests a new mRNA vaccine that helps your immune system fight cancer cells linked to the Epstein-Barr virus. It may be an option for people with advanced EBV-positive cancers that have not responded to standard treatments.
This trial tests an investigational drug (WGc-043) for people with advanced solid tumors that are positive for the Epstein-Barr virus (EBV). The goal is to see if the drug is safe and how well it works, and it might help shrink tumors or slow their growth.
Hear when a new Epstein-Barr Virus Associated Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.